期刊文献+

胰腺癌术后肝转移的治疗策略及预后分析 被引量:8

Prognostic analysis of asynchronous liver metastasis in patients with pancreatic cancer
收藏 分享 导出
摘要 目的分析胰腺癌术后非同期肝转移患者的治疗过程和疗效及不同治疗策略对患者生存期的影响。方法回顾性分析福建医科大学附属协和医院2006年1月至2012年1月所收治的48例胰腺癌术后肝转移患者的病例资料。结果48例胰腺癌患者中术后6个月内发生肝转移27例,1、3、5年生存率分别为22.2%、3.7%和0,中位生存时间为6个月;6个月以上发生肝转移21例,1、3、5年生存率分别为85.7%、30.6%和9.2%,中位生存时间为15个月,两者差异有统计学意义(P〈0.01)。胰腺癌术后行吉西他滨化疗者6个月内发生肝转移的概率为33.3%(8/24),1、3、5年无病(无肝转移)生存率分别为20.8%、4.3%、0,中位无病生存时间为8个月;未行术后化疗者6个月内发生肝转移的概率为79.2%(19/24),l、3、5年无病(无肝转移)生存率分别为4.2%、0、0,中位无病生存时间为3个月,两者差异均有统计学意义(P值均〈0.01)。胰腺癌术后化疗联合肝转移癌切除患者总体生存率优于其他治疗组(P值均〈0.01);术后化疗联合介入治疗患者总体生存率优于单纯介入组、化疗组和未行针对肿瘤治疗的临床观察组(P值均〈0.05);介入组、化疗组和临床观察组患者总体生存率差异无统计学意义。结论胰腺癌根治术后6个月内发生肝转移的患者预后较差,术后化疗能延缓肝转移发生时间。对可切除患者,化疗联合手术切除肝转移灶是首选治疗方法,化疗联合介入治疗疗效优于单一种治疗。 Objective To analyse tratment strategies and to evaluate the relation between different therapies and survival rate of patients of with asynchronous liver metastases after pancreatic cancer surgery (PCLM). Methods From January 2006 to January 2012, 48 patients with PCLM were included in this study, and their medical records were retrospectively analyzed. Results Among the 48 patients, 27 cases of liver metastases were found within six months after surgery, and the survival rate for 1, 3 and 5 years was 22.2% , 3.7% and 0% , respectively, with the median survival of 6 months, and 21 cases of liver metastases were found after six months, and the survival rate for 1, 3 and 5 years was 85.7% , 30.6% and 9.2% , with the median survival of 15 months, and the difference between the two groups was statistically significant ( P 〈 O. 01 ). After pancreatic cancer surgery and adjuvant gemcitabine chemotherapy, the probabi|ity of liver metastases was 33.3% (8/24) within six months, the median disease-free survival time was 8 months and the disease-free survival rate for 1, 3 and 5 years was 20.8% , 4.3% and 0%. For patients without adjuvant gemcitabine chemotherapy, the probability of liver metastases was 79.2% ( 19/24 ) , the median disease-free survival time was 3 months and the disease-free survival rate for 1, 3 and 5 years was 4.2% , 0% and 0% , and the difference between the two groups was statistically significant (P 〈0.01 ). The overall survival for patients undergoing resection of liver metastases combined with gemcitabine treatment was better than the other groups (P 〈 0.01 ). And the overall survival for patients undergoing transhepatic arterial embolization (TACE) combined with gemcitabine treatment was better than TACE group, gemcitabine group or the observation group (P 〈0.05 ). There were no difference in overall survival between TACE group, gemcitabine group and observation group. Conclusions Pancreatic cancer patients who develop liver metastasis within six months af
作者 孟泽武 陈燕凌 朱金海 韩圣华 周良艺 Meng Zewu, Chen Yanling, Zhu Jinhai, Han Shenghua, Zhou Liangyi(Department of Hepatobiliary Surgery, Union Hospital, Fujian Medical University, Fuzhou 350001, China)
出处 《中华胰腺病杂志》 CAS 2015年第1期34-38,共5页 Chinese JOurnal of Pancreatology
关键词 胰腺肿瘤 肝转移 手术后期间 预后 Pancreatic neoplasms Liver metastasis Postoperative period Prognosis
  • 相关文献

参考文献2

二级参考文献23

  • 1胡先贵,金钢,刘瑞,张怡杰,胡志浩,邵成浩,唐岩.联合腹腔干切除的胰体尾癌扩大根治术(附11例报告)[J].第二军医大学学报,2005,26(8):871-872. 被引量:5
  • 2胡先贵,金钢,张怡杰,刘瑞,邵成浩,唐岩.先行门-肠系膜上静脉重建的扩大胰十二指肠切除术[J].外科理论与实践,2007,12(3):218-220. 被引量:6
  • 3胰腺癌诊治指南[J].中华外科杂志,2007,45(19):1297-1299. 被引量:12
  • 4Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin,2014,64( 1 ) :9-29. 被引量:1
  • 5National Comprehensive Cancer Network. Clinical Practice Guide- lines in Oncology. Pancreatic Adenocarcinoma [ S ]. Version 2. 2014. http://www, nccn. org/professionals/physician_ gls/f guidelines, asp. 被引量:1
  • 6Sobin LH, Gospodarowicz MK, Wittekind C, et al. TNM classifi-cation of malignant tumours[ M ]. 7th ed. Hoboken: Wiley-Black- well ,2010. 被引量:1
  • 7Asbun HJ, Conlon K, Fernandez-Cruz L, et al. When to perform a pancreatoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery[ J]. Surgery,2014,155 ( 5 ) :887-892. 被引量:1
  • 8Japan Pancreas Society. Classification of Pancreatic Carcinoma [ M]. Second English ed. Tokyo: Kanehara & Co. , Ltd. ,2003. 被引量:1
  • 9Nimura Y, Nagino M, Takao S, et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal ade- nocarcinoma of the head of the pancreas. Long-term results of a Japanese multicenter randomized controlled trial [ J ]. J Hepatobili- ary Pancreat Sci,2012,19 (3) :230-241. 被引量:1
  • 10Jang JY, Kang MJ, Heo JS, et al. A prospective randomized con- trolled study comparing outcomes of standard resection and extend- ed resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer [J]. Ann Surg,2014,259 (4) :656-664. 被引量:1

共引文献60

同被引文献81

  • 1熊奎,况建荣,李超,王道梅,马玉芳.三维适形技术在射频消融治疗原发性肝癌中的应用[J].肿瘤防治研究,2005,32(8):513-514. 被引量:9
  • 2刘德华,华阳,王少雷,李森,罗娅红.肝动脉栓塞化疗与灌注化疗介入治疗结肠癌肝转移瘤的临床研究[J].中国全科医学,2006,9(3):211-212. 被引量:6
  • 3赵玉沛.胰腺癌诊治存在的问题与争议[J].中华消化外科杂志,2007,6(4):249-251. 被引量:17
  • 4He Y, Zheng R, Li D, et al. Pancreatic cancer incidence and mortality patterns in China, 2011 [J]. Chin J Cancer Res, 2015, 27(1) :29-37. 被引量:1
  • 5Yu HJ, Jung JY, Jeong JH, et al. Induction of apoptosis by parthenolide in human oral cancer cell lines and tumor xenografts [J]. Oral Oncol, 2015, 51(6) :602-609. 被引量:1
  • 6Galteland E, Sivertsen EA, Svendsrud DH, et al. Translocation t (14;18) and gain of chromosome 18/BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin's lymphomas [J]. Leukemia, 2005, 19(12) :2313-2323. 被引量:1
  • 7Yan LX, Liu YH, Luo DL, et al. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified[J]. PLoS One, 2014, 9(8) :el04068. 被引量:1
  • 8Abdel-Fatah TM, Perry C, Dickinson P, et al. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings [ J ]. Ann Oncol, 2013, 24 ( 11 ) :2801-807. 被引量:1
  • 9O'Malley DP, Chizhevsky V, Grimm KE, et al. Utility of BCL2, PD1, and CD25 immunohistoehemieal expression in the diagnosis ofT-cell lymphomas [J]. Appl Immunohistochem Mol Morphol, 2014, 22(2) :99-104. 被引量:1
  • 10Krskov6 L, Kalinovt M, Brizov6 H, et al. Molecular and immunohistochemical analyses of BCL2, KI-67, and cyclin D1 expression in synovial sarcoma [ J ]. Cancer Genet Cytogenet, 2009, 193(1) :1-8. 被引量:1

引证文献8

二级引证文献9

投稿分析
职称考试

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈